LivaNova's share price and revenue have been falling for five years, worrying investors. However, the CEO's modest pay could be a positive. The company's future growth is uncertain.
The company's low P/S, despite strong revenue growth, is tied to weaker future revenue forecasts compared to the industry, deterring investors, which hinders the P/S ratio from increasing. A rise in future revenue is needed to justify a higher P/S ratio.
With a continuous trend of declining ROCE, LivaNova's growth seems doubtful. Under competitive pressures and being a matured enterprise, suggestions lean towards considering other investment options.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
LivaNova Stock Forum
watching this one around 9am
keep these on watch $LivaNova (LIVN.US)$ $1847 Holdings (EFSH.US)$ $Healthy Choice Wellness (HCWC.US)$ $Allarity Therapeutics (ALLR.US)$ $Fly-E (FLYE.US)$ $N2OFF (NITO.US)$ $Syra Health (SYRA.US)$
apextradez 👈🏻 hind us for more alerts led by the Best Alpha.Scorpio
• $Banc of California (BANC.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers (CFR.US)$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger (GWW.US)$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc (INVH.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp (PCB.US)$: Raymond James Upgrades to Outperform from Market Perfor...
No comment yet